Novartis AG
NYSE:NVS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Novartis AG
NYSE:NVS
|
CH |
|
L
|
Lifestyle Communities Ltd
OTC:LCOMF
|
AU |
Intrinsic Value
The intrinsic value of 
Novartis AG (NVS) under the Base Case is 107.133 USD per share.
Compared with the current market price of 161.205 USD, the stock appears
Overvalued by 34% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Novartis Does
Novartis AG is a global drugmaker that discovers, develops, manufactures, and sells prescription medicines. Its main products are branded treatments for serious illnesses, including cancer, immune diseases, heart and kidney conditions, eye disease, and some rare disorders. It does not sell everyday consumer health products; its business is centered on medicines that doctors prescribe to patients.
- Headquarters
- Switzerland CH
- Employees
- 75 267
- IPO date
- May 7, 2001
Novartis has no economic moat
Patent protection keeps copies of individual Novartis medicines out temporarily, but it does not permanently prevent competitors from taking sales. Generic competition affecting medicines such as Entresto and Tasigna shows why successful products alone do not ensure lasting protection across the company.
Read the full moat analysis
Revenue & Expenses Breakdown
Novartis AG
Earnings Waterfall
Novartis AG
The intrinsic value for Novartis AG (NVS) under the Base Case is 107.133 USD.
Compared with the current market price of 161.205 USD, the stock appears Overvalued by 34% .